<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04171726</url>
  </required_header>
  <id_info>
    <org_study_id>REDOX TAVI</org_study_id>
    <nct_id>NCT04171726</nct_id>
  </id_info>
  <brief_title>Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation</brief_title>
  <acronym>REDOX TAVI</acronym>
  <official_title>Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-center, investigator-initiated, single arm interventional study in patients
      undergoing transfemoral transcatheter aortic valve replacement (TAVR) in the Erasmus Medical
      Center in Rotterdam (NL). Study population will be patients undergoing TAVR with no formal
      indication for oral anticoagulant (OAC) and no dual antiplatelet therapy (DAPT) requirement
      for coronary stents. Primary endpoint is the incidence of leaflet thickening on MSCT after
      three months of edoxaban treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Thromboembolic- and bleeding events can occur after TAVI and can have great
      consequences. There is currently no evidence-based guideline on prevention of thromboembolic
      events after TAVI and the current standard of care with DAPT 3-6 months is based on expert
      opinion. Recently multislice computed tomography (MSCT) studies identified bioprosthesis
      leaflet thickening and impaired leaflet motion after TAVI. The goal of this study is to
      investigate whether in TAVI patients, treatment with edoxaban leads to a reduction in leaflet
      thickening incidence after 3 months and whether it is safe and clinically efficient.

      Objective: To investigate whether treatment with edoxaban leads to a decrease in incidence of
      leaflet thickening and is clinical efficient and safe.

      Study design: A single-center, investigator-initiated, open-label, observational study.

      Study population: Patients undergoing transfemoral transcatheter aortic valve replacement in
      the Erasmus University Medical Center with no formal novel oral
      anticoagulants/vitamin-K-antagonist (NOAC/VKA) indication.

      Intervention (if applicable): Patients will be treated with edoxaban for a period of 3 months
      following TAVI. Afterwards they will switch to acetylsalicylic acid.

      Main study parameters/endpoints: The incidence of leaflet thickening on MSCT 3 months after
      TAVI and edoxaban treatment.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness: Thus far edoxaban has proven to be safe and non-inferior to treatment with
      warfarin in several indications. The role of anticoagulant agents in TAVI still has to be
      unravelled. Subjects participating in this trial are possibly at higher risk for bleeding
      complications than patients being treated with dual antiplatelet therapy after TAVI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of aortic valve leaflet thickening after TAVI as assessed by cardiac 4D computed tomography scan (4DCT)</measure>
    <time_frame>3 months after TAVI</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Edoxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>A non-vitamin K antagonist (VKA) oral anticoagulant that selectively inhibits factor Xa.</description>
    <arm_group_label>Edoxaban</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed successful elective TAVI for severe native aortic valve stenosis with any
             commercially-available transcatheter heart valve (THV).

               -  Correct positioning of a single prosthetic heart valve

               -  Device success, defined by:

                    -  Mean aortic valve gradient &lt; 20 mmHg

                    -  Peak transvalvular velocity &lt; 3.0 m/s

                    -  Aortic valve regurgitation of 2 or less

          -  No periprocedural complications.

               -  No overt stroke

               -  No uncontrolled bleeding

               -  No major vascular complication defined by the Valve academic research committee 2
                  (VARC-2) consensus

          -  No formal indication for oral anticoagulation

               -  Prevention of thromboembolic complications in patients with atrial fibrillation

               -  Prevention for recurrent venous thromboembolism

               -  Prevention for recurrent pulmonary embolism

        Exclusion Criteria:

          -  History of life-threatening or major bleeding event ≥ Bleeding academic research
             committee (BARC) 3b definitions within the last year.

          -  Conditions with a high risk of bleeding

               -  Active peptic ulcer or upper gastrointestinal bleeding (&lt; 3 months)

               -  Malignancy with high risk of bleeding

               -  Recent unresolved brain of spinal injury

               -  Spinal or ophthalmic surgery within last 3 months prior to enrolment

               -  Intracranial haemorrhage

               -  Esophagal varices

               -  Arteriovenous malformations with high risk of bleeding

               -  Vascular aneurysms

               -  Major intraspinal or intracerebral vascular abnormalities

          -  Hypersensitivity or contraindications to edoxaban

          -  No percutaneous coronary intervention within 6 months prior to randomization
             (requiring DAPT after TAVR)

          -  Dialysis-dependency or glomerular filtration rate &lt; 30 mL/min at time of enrollment

          -  Active bleeding or bleeding diathesis including thrombocytopenia (platelet count &lt;
             50.000 cells/UL), thromboasthenia, haemophilia or von Willebrand disease

          -  Patients unable to adhere to or complete the investigational protocol for any reason
             including but not limited to geographical residence, psychiatric condition or
             life-threatening disease

          -  Pregnant or breast-feeding subjects

          -  Current participation in clinical trials that potentially interfere with the current
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolas M Van Mieghem, MD, PhD</last_name>
    <phone>+31(0)107035260</phone>
    <email>n.vanmieghem@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maarten P van Wiechen, MD</last_name>
    <phone>+31(0)107038896</phone>
    <email>m.vanwiechen@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas M van Mieghem, MD, PhD</last_name>
      <phone>+31(0)107035260</phone>
      <email>n.vanmieghem@erasmusmc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, De Backer O, Asch FM, Ruiz CE, Olsen NT, Trento A, Friedman J, Berman D, Cheng W, Kashif M, Jelnin V, Kliger CA, Guo H, Pichard AD, Weissman NJ, Kapadia S, Manasse E, Bhatt DL, Leon MB, Søndergaard L. Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med. 2015 Nov 19;373(21):2015-24. doi: 10.1056/NEJMoa1509233. Epub 2015 Oct 5.</citation>
    <PMID>26436963</PMID>
  </reference>
  <reference>
    <citation>Sondergaard L, De Backer O, Kofoed KF, Jilaihawi H, Fuchs A, Chakravarty T, Kashif M, Kazuno Y, Kawamori H, Maeno Y, Bieliauskas G, Guo H, Stone GW, Makkar R. Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves. Eur Heart J. 2017 Jul 21;38(28):2201-2207. doi: 10.1093/eurheartj/ehx369.</citation>
    <PMID>28838044</PMID>
  </reference>
  <reference>
    <citation>Chakravarty T, Søndergaard L, Friedman J, De Backer O, Berman D, Kofoed KF, Jilaihawi H, Shiota T, Abramowitz Y, Jørgensen TH, Rami T, Israr S, Fontana G, de Knegt M, Fuchs A, Lyden P, Trento A, Bhatt DL, Leon MB, Makkar RR; RESOLVE; SAVORY Investigators. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017 Jun 17;389(10087):2383-2392. doi: 10.1016/S0140-6736(17)30757-2. Epub 2017 Mar 19.</citation>
    <PMID>28330690</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Nicolas van Mieghem</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Thrombosis</keyword>
  <keyword>Aortic Valve Stenosis</keyword>
  <keyword>Heart Valve Diseases</keyword>
  <keyword>Ventricular Outflow Obstruction</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Embolism and Thrombosis</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Factor Xa Inhibitors</keyword>
  <keyword>Anticoagulants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

